Oestradiol reduces Liver Receptor Homolog-1 mRNA transcript stability in breast cancer cell lines
Creators
- 1. Environmental and Biotechnology Centre, Swinburne University, Hawthorn, Victoria 3122 (Australia)
- 2. Cancer Drug Discovery Laboratory, Prince Henry's Institute of Medical Research, Clayton, Victoria 3168 (Australia)
- 3. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3168 (Australia)
Description
Highlights: •LRH-1 is an orphan nuclear receptor that regulates tumor proliferation. •In breast cancer, high mRNA expression is associated with ER+ status. •In ER−ve cells, despite very low mRNA, we found abundant LRH-1 protein. •Our data show distinctly different LRH-1 protein isoforms in ER− and ER+ breast cancer cells. •This is due to differences in LRH-1 mRNA and protein stability rates. -- Abstract: The expression of orphan nuclear receptor Liver Receptor Homolog-1 (LRH-1) is elevated in breast cancer and promotes proliferation, migration and invasion in vitro. LRH-1 expression is regulated by oestrogen (E2), with LRH-1 mRNA transcript levels higher in oestrogen receptor α (ERα) positive (ER+) breast cancer cells compared to ER− cells. However, the presence of LRH-1 protein in ER− cells suggests discordance between mRNA transcript levels and protein expression. To understand this, we investigated the impact of mRNA and protein stability in determining LRH-1 protein levels in breast cancer cells. LRH-1 transcript levels were significantly higher in ER+ versus ER− breast cancer cells lines; however LRH-1 protein was expressed at similar levels. We found LRH-1 mRNA and protein was more stable in ER− compared to ER+ cell lines. The tumor-specific LRH-1 variant isoform, LRH-1v4, which is highly responsive to E2, showed increased mRNA stability in ER− versus ER+ cells. In addition, in MCF-7 and T47-D cell lines, LRH-1 total mRNA stability was reduced with E2 treatment, this effect mediated by ERα. Our data demonstrates that in ER− cells, increased mRNA and protein stability contribute to the abundant protein expression levels. Expression and immunolocalisation of LRH-1 in ER− cells as well as ER− tumors suggests a possible role in the development of ER− tumors. The modulation of LRH-1 bioactivity may therefore be beneficial as a treatment option in both ER− and ER+ breast cancer
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2013.07.101Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2013.07.101;
- PII
- S0006-291X(13)01275-8;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 438
- Journal Issue
- 3
- Journal Page Range
- p. 533-539
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 45063201
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- IN VITRO; LIVER; MAMMARY GLANDS; MESSENGER-RNA; NEOPLASMS; RECEPTORS
- Descriptors DEC
- BODY; DIGESTIVE SYSTEM; DISEASES; GLANDS; MEMBRANE PROTEINS; NUCLEIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PROTEINS; RNA
Optional Information
- Copyright
- Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.